Founded in 1978, Biogen stands as one of the world's first global biotechnology companies, pioneering innovative science to deliver transformative medicines for patients facing devastating neurological diseases. Headquartered in Cambridge, Massachusetts with major manufacturing operations in North Carolina's Research Triangle Park, Biogen has spent nearly 50 years pushing the boundaries of what's possible in biotechnology. The company focuses on some of the most challenging disease areas including multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, lupus, and postpartum depression.
Biogen's mission is rooted in deep scientific expertise and the courage to take bold risks. With close to 2,500 U.S. employees in research and development alone, plus over 1,500 manufacturing employees in North Carolina, Biogen leverages its understanding of human biology to advance first-in-class treatments and therapies. The company's culture - described as "Caring Deeply. Working Fearlessly. Changing Lives™" - reflects its unwavering commitment to patients, combining rigorous science with a profound sense of purpose to create value for shareholders and communities worldwide. Through continuous innovation in neurology, immunology, and rare diseases, Biogen aims to turn scientific breakthroughs into tangible hope for millions of patients.